GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » YoY Rev. per Sh. Growth

Apollon Formularies (AQSE:APOL) YoY Rev. per Sh. Growth : 0.00% (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Apollon Formularies's YoY Rev. per Sh. Growth for the quarter that ended in Jun. 2023 was 0.00%.

Apollon Formularies's Revenue per Share for the six months ended in Jun. 2023 was £0.00.


Apollon Formularies YoY Rev. per Sh. Growth Historical Data

The historical data trend for Apollon Formularies's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies YoY Rev. per Sh. Growth Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 6,900.00 -100.00 - -

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Apollon Formularies YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Apollon Formularies's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2021 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2021 )
=(Revenue per Share (A: Dec. 2021 )-Revenue per Share (A: Dec. 2020 ))/ | Revenue per Share (A: Dec. 2020 ) |
=(0-0)/ | 0 |
=N/A %

Apollon Formularies's YoY Rev. per Sh. Growth for the quarter that ended in Jun. 2023 is calculated as:

YoY Rev. per Sh. Growth (Q: Jun. 2023 )
=(Revenue per Share (Q: Jun. 2023 )-Revenue per Share (Q: Dec. 2021 )) / | Revenue per Share (Q: Dec. 2021 )) |
=(0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apollon Formularies YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

5-Star Predictable Companies with Highest ROA

By Holly LaFon Holly LaFon 03-20-2012

6 Highly Predictable Companies with Historically Low P/S Ratios

By Dianne Tordillo Dianne Tordillo 11-27-2012

Apollo Education Group Is a Value Trap

By OPM Insights Nelson Hsu 10-15-2015

Yacktman Fund Comments on Apollo

By Holly LaFon Holly LaFon 02-05-2016

Valuing Donald Yacktman's Portfolio: The Peter Lynch Fair Value

By Holly LaFon Holly LaFon 07-02-2012

7 Arbitrage Trades With High Profit Potential

By Jonathan Poland Jonathan Poland 11-30-2016

FPA Capital Fund new buys in Q2 2015

By Tiziano Frateschi Tiziano Frateschi 07-14-2015

Weekly 3-Year Low Highlights: APOL, PDLI, TC, ALLT, ELRC

By Jimmy Xiao gurujx 05-17-2015

First Pacific Advisors Buys Alcoa, Bank of America

By Tiziano Frateschi Tiziano Frateschi 10-16-2015

Apollo Group: This Unloved Company Is Significantly Undervalued

By Matthew Dow Matthew Dow 05-09-2013